**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 83657

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Clinical association between coagulation indicators and bone metastasis in patients with gastric cancer**

Wang X *et al*. Coagulation indicators predict bone metastasis

Xuan Wang, Jing-Ya Wang, Min Chen, Juan Ren, Xin Zhang

**Xuan Wang, Min Chen, Juan Ren,** Department of Radiotherapy and Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China

**Jing-Ya Wang,** Department of Gastroenterology, Xi'an Children's Hospital, Shaanxi Research Institute for Pediatric Diseases, The Affiliated Children's Hospital of Xi'an Jiaotong University and National Regional Medical Center for Children (Northwest), Xi'an 710003, Shaanxi Province, China

**Xin Zhang,** Department of Surgical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China

**Author contributions:** Wang X, Ren J and Zhang X designed the research study; Wang X, Wang JY and Chen M performed the research; Wang X analyzed the data and wrote the manuscript; all authors read and approve the final manuscript.

**Corresponding author: Xin Zhang, MD,** **Doctor,** Department of Surgical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 West Yanta Road, Xi'an 710061, Shaanxi Province, China.zhangxinzh@stu.xjtu.edu.cn

**Received:** February 6, 2023

**Revised:** March 16, 2023

**Accepted:** May 6, 2023

**Published online:** June 15, 2023

**Abstract**

BACKGROUND

Bones are one of the most common target organs for cancer metastasis. Early evaluation of bone metastasis (BM) status is clinically signiﬁcant. Cancer patients often experience a hypercoagulable state.

AIM

To evaluate the correlation between coagulation indicators and the burden of BM in gastric cancer (GC).

METHODS

We conducted a single-center retrospective study and enrolled 454 patients. Clinical information including routine blood examination and coagulation markers were collected before any treatment. Patients were grouped according to the status of BM. Receiver operating characteristic curves were used to assess diagnostic performance and determine the optimal cutoff values of the above indicators. Cutoff values, sensitivity and specificity were based on the maximum Youden index. Univariate and multivariate logistic regression analyses were used to evaluate the relationships between biomarkers and BM.

RESULTS

Ofthe 454 enrolled patients, 191 patients were diagnosed with BM. The receiver operating characteristic curve analysis suggested that prothrombin time (PT) [cutoff: 13.25; sensitivity: 0.651; specificity: 0.709; area under receiver operating characteristic curve (AUC) = 0.738], activated partial thromboplastin time (aPTT) (cutoff: 35.15; sensitivity: 0.640; specificity: 0.640; AUC = 0.678) and fibrin degradation products (FDP) (cutoff: 2.75; sensitivity: 0.668; specificity: 0.801; AUC = 0.768) act as novel predictors for BM. Based on multivariate logistic regression analysis, the results showed the independent correlation between PT [odds ratio (OR): 3.16; 95% confidence interval (CI): 1.612-6.194; *P* = 0.001], aPTT (OR: 2.234; 95%CI: 1.157-4.313; *P* = 0.017) and FDP (OR: 3.17; 95%CI: 1.637-6.139; *P* = 0.001) and BM in patients with GC. Moreover, age, carcinoembryonic antigen, erythrocyte and globulin were found to be significantly associated with BM.

CONCLUSION

Coagulation markers, namely PT, aPTT and FDP, might be potential predictors for screening BM in patients with GC.

**Key Words:** Gastric cancer; Bone metastasis; Coagulation markers; Risk factor; Activated partial thromboplastin time; Prothrombin time; Fibrin degradation products

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Wang X, Wang JY, Chen M, Ren J, Zhang X. Clinical association between coagulation indicators and bone metastasis in patients with gastric cancer. *World J Gastrointest Oncol* 2023; 15(7): 1253-1261

**URL**: https://www.wjgnet.com/1948-5204/full/v15/i7/1253.htm

**DOI**: https://dx.doi.org/10.4251/wjgo.v15.i7.1253

**Core Tip:** Bones are one of the most common organs involved in cancer metastasis. Early evaluation of bone metastasis (BM) status is clinically signiﬁcant. In this study, we confirmed that coagulation markers (prothrombin time, activated partial thromboplastin time and fibrin degradation products), carcinoembryonic antigen and globulin are independent risk factors for BM in patients with gastric cancer. Patients with these risk factors should be screened early for BM, which may significantly decrease mortality rates related to BM in patients with gastric cancer.

**INTRODUCTION**

Gastric cancer (GC) is one of the most malignant neoplasms worldwide. According to GLOBOCAN’s 2020 statistics, there were approximately 1.089 million new GC cases and 769000 GC deaths worldwide. GC has the fifth highest incidence rate and the fourth highest mortality rate of all cancers[1].

Common metastatic sites of GC are the liver, lungs, and peritoneum. Bone metastasis (BM) is relatively rare, ranging from 0.9% to 3.8%[2,3].However, this incidence has been as high as 13.4% in autopsies[4]. The majority of patients with BM have several symptoms including bone pain, mobility disorders, hypercalcemia, pathological fractures and spinal cord compression, which seriously affects their quality of life. Unfortunately, BM is often underdiagnosed because sensitive diagnostic tests are recommended only after the onset of clinical symptoms. In addition, the median survival time for patients with GC-related BM is only 3-6 mo[3,5].

Imaging is currently the most important diagnostic method for BM. Elevated serum tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and bone-associated alkaline phosphatase (ALP) provide additional diagnostic significance[6,7]. Computed tomography (CT) or enhanced CT is not a routine test for BM screening. It is only recommended when the patient is symptomatic, which leads to asymptomatic BM in patients with GC being largely undetected[4]. Previous studies have found that fibrinogen, activated partial thromboplastin time (aPTT) and D-dimer are independent risk factors for BM in non-small cell lung cancer[8]. However, there has been little research on multiple risk factors, such as a combination of clinical data and laboratory indicators, for BM in patients with GC. This study explored risk factors for BM from GC through multivariate analysis based on laboratory tests.

**MATERIALS AND METHODS**

***Patients***

We retrospectively collected data on patients diagnosed with GC at the First Affiliated Hospital of Xi’an Jiaotong University from January 2014 to January 2019. The inclusion criteria were no distant metastases or BM. Exclusion criteria included: (1) A history of thrombotic disease, anticoagulant therapy or antiplatelet therapy; (2) Acute infection or disseminated intravascular coagulation; and (3) Lack of pretreatment laboratory data. In total, 454 patients were enrolled in this study. Data evaluated included sex, age at diagnosis, preoperative routine blood examination (erythrocyte, hemoglobin, leukocyte, neutrophil, lymphocyte, monocyte and platelet), glucose, albumin, globulin, CEA, CA19-9, CA72-4 and coagulation markers including prothrombin time (PT), prothrombin ratio (PTR), international normalized ratio (INR), aPTT, thrombin time (TT), fibrinogen, D-dimer and fibrin degradation products (FDP). Laboratory indicators were collected before any treatment. Blood parameters were those closest to the time of treatment. This study was approved by the Ethics Committee of First Affiliated Hospital of Xi’an Jiaotong University.

***Statistical analysis***

Cases were grouped according to BM status. Categorical variables were expressed as frequency (percentage) and compared using the *χ2* test. Continuous variables were expressed as mean and standard deviation or median and interquartile range depending on whether they were normally distributed. Normally distributed continuous variables were compared using the Student’s *t-*test. Continuous variables that were not normally distributed were compared using the Mann-Whitney *U* test. The parameters with significant differences between the control group and the BM group were selected for receiver operating characteristic (ROC) analysis. The optimal cutoff values for parameters were obtained by ROC analyses based on the Youden index. The prediction probability (PP) of combined ROC curve was obtained by binary logistic regression. Multivariate logistic regression was performed to assess the relationship between laboratory variables and BM status. Statistical analyses and data plotting were performed with SPSS Statistics (version 20.0; IBM Corp., Armonk, NY, United States). A two-sided *P* value < 0.05 was considered statistically significant.

**RESULTS**

***Patient characteristics***

We collected data from 454 patients with GC and grouped them according to the method described previously. As shown in Table 1, there were 191 cases in the BM group. The median age of patients was 61 years, and males comprised the majority of patients (73.8%). Patients with BM had higher levels of GC markers (CEA, CA19-9 and CA72-4), neutrophils, glucose, globulin and most coagulation parameters (PT, PTR, INR, aPTT, fibrinogen, D-dimer and FDP) (all *P* < 0.001). Moreover, erythrocyte, lymphocyte and platelet levels were significantly lower in the BM group (all *P* <0.05) (Table 1).

***BM in patients with GC can be predicted by novel tumor markers PT, aPTT and FDP***

We performed ROC analysis to assess the efficacy of parameters to predict BM in patients with GC and obtained a series of cutoff values. The optimal cutoff values (sensitivity and specificity) were: age, 59.5 (54.6% and 58.3%); CEA, 3.97 (64.9% and 71.1%); CA19-9, 12.81 (65.5% and 64.9%); CA72-4, 6.71 (51.8% and 74.7%); erythrocyte level, 4.43 (42.3% and 79.7%); hemoglobin, 133.5 (42.7% and 75.9%); leukocyte level, 6.28 (49.2% and 68.5%); neutrophil level, 4.23 (48.4% and 74.9%); lymphocyte level, 1.43 (55.2% and 64.2%); platelet level, 167.5 (73.1% and 44.9%); glucose, 4.82 (52.4% and 74.8%); globulin, 28.75 (50.0% and 81.4%); PT, 13.25 (65.1% and 70.9%); PTR, 1.09 (40.7% and 78.5%); INR, 1.1 (37.6% and 81.9%); aPTT, 35.15 (64.0% and 64.0%); TT, 15.95 (69.7% and 48.7%); fibrinogen, 4.06 (42.3% and 82.0%); D-dimer, 1.03 (69.0% and 72.8%); FDP, 2.75 (66.8% and 80.1%) (Figure 1, Supplementary Figures 1 and 2). The area under ROC curves and 95% confidence intervals (CI) were: CEA, 0.694 (0.639-0.748); CA19-9, 0.673 (0.617-0.729); CA72-4, 0.624 (0.560-0.688); PT, 0.738 (0.692-0.784); aPTT, 0.678 (0.629-0.727); and FDP, 0.768 (0.722-0.814) (Table 2, Figure 1).

Parameters were grouped by aforementioned cutoff values. Multivariate logistic regression analysis showed that higher PT [odds ratio (OR): 3.16; 95%CI: 1.612-6.194; *P* = 0.001), higher aPTT (OR: 2.234; 95%CI: 1.157-4.313; *P* = 0.017) and elevated FDP (OR: 3.17; 95%CI: 1.637-6.139; *P* = 0.001) were independent risk factors for BM in patients with GC. In addition, higher CEA and globulin as well as lower age and red blood cell count were also independent risk factors for BM with an OR (95%CI) of 2.847 (1.496-5.418), 4.253 (2.114-8.558), 0.392 (0.203-0.756), and 0.482 (0.24-0.966), respectively (all *P* < 0.05) (Table 3). The area under ROC curve (95%CI) of PP was 0.879 (0.841-0.917) with a sensitivity of 0.831 and a specificity of 0.806 (Table 2, Figure 1).

**DISCUSSION**

BM is a common complication of certain cancers, including breast cancer and prostate cancer[9], whereas BM due to GC is less frequent[10]. The common metastatic sites of GC are the liver, lungs and peritoneum. Most patients with BM due to GC have multiple metastases, and most metastases are difficult to resect surgically[11]. Once tumors have metastasized to the bone, they are virtually incurable and cause severe morbidity before the patient dies. BM leads to pain, pathological fractures, nerve compression syndrome and hypercalcemia. According to relevant research reports, the proportion of patients suspected of BM due to GC found by bone scan screening was as high as 25.0%-45.3%[12].

Several factors have been shown to have predictive value for BM due to GC. BM is a dynamic process of osteolytic and osteogenesis mediated by osteoclasts that disrupts normal bone homeostasis. Bone ALP is an indicator of osteoblast metabolism and a relatively specific osteogenic marker, which has predictive value in patients with BM due to GC[6]. Bone screening is recommended for cancer types with a high incidence of BM, such as prostate cancer, breast cancer, small cell lung cancer and renal cell carcinoma. A variety of imaging studies are available, including plain X-rays, bone scintigraphy, CT scans, magnetic resonance imaging, positron emission tomography and positron emission tomography/CT, to assess bone involvement. However, bone screening has not been routinely recommended by the Chinese Society of Clinical Oncology for patients with GC[13]. Excessive X-rays and CT imaging are expensive and put patients at risk of unnecessary radiation exposure and/or invasive procedures due to false positive results. Therefore, it is necessary to evaluate BM through a combination of imaging and analyzing hematological parameters and patient symptoms.

In this study, we screened possible risk factors for BM by comparing baseline data between the control group and the BM group. Through multivariate logistic regression analysis of candidate tumor markers, routine blood counts, coagulation indicators, albumin and globulin, we found that elevated CEA, globulin, PT, aPTT and FDP and younger age and lower red blood cells were independent risk factors for BM due to GC. CEA is a classic GC marker and has been shown to be a risk factor for distant metastasis and lymph node metastasis[14,15]. Globulin was identified as an independent predictor of occult metastasis in the neck of oral squamous cell carcinoma[16]. In GC, a high level of globulin is a valuable predictor of tumor progression[17].

Tumors are often accompanied by a state of coagulation activation[18]. Fibrinogen, aPTT and D-dimer were found to be risk factors for BM in non-small cell lung carcinoma patients[19]. Our study confirmed that PT, aPTT and FDP, as coagulation indicators, are independent predictors of BM in GC patients. In fact, tumor cells often express tissue factor or other procoagulants that can initiate coagulation[20]. There is considerable evidence that inhibiting coagulation can inhibit tumor metastasis[21,22]. BM due to GC can develop regardless of the tumor stage, although the proportion of patients with stage IV GC with BM exceeds the proportion of patients with stages I-III combined. It was found that even after radical gastrectomy, BM recurred in 1.8% of patients[23]. This indicates that the risk of BM should be considered when these indicators are abnormally elevated in patients with GC, especially when they are higher than the cutoff values in Table 2. Furthermore, the cutoff values of the BM risk factors indicated in this study are different from their respective upper limits of clinical normality. In other words, elevated coagulation indicators may indicate BM risk even within the range of clinically normal reference values.

A hypercoagulable state represents a heterogeneous group of disorders that cover a variety of risk factors such as thrombosis, obesity, pregnancy, cancer and its treatment, antiphospholipid antibody syndrome, heparin-induced thrombocytopenia and myeloproliferative disorders[24]. This suggests that in order to improve the specificity of coagulation factors in assessing BM due to GC, other factors that may affect their levels need to be excluded. Although we discovered independent risk factors for BM due to GC, we did not explore whether they were specific to BM or due to other metastatic sites’ GC.

Because we retrospectively collected data from patients with GC, bone-associated ALP was not routinely tested and was not included in the analysis. There is evidence that tumor-induced hypercoagulability and fibrin formation are required for tumor angiogenesis, metastasis and invasion because cross-linked fibrin in the extracellular matrix may be the framework for tumor cell migration during invasion. Based on this, circulating tumor cells and micrometastases are considered early events in the process of tumor cell metastasis[25]. Bone ALP is a specific marker of osteoblast metabolism and is significantly associated with the presence and degree of bone involvement in metastatic tumors. Bone-associated ALP has been shown to be an important predictor of BM in patients with breast and prostate cancer[26]. More than half of patients with BM due to GC have elevated ALP and tumor markers[3,6]. Coagulation indexes and bone ALP reflect the two stages of tumor hematogenous metastasis and BM, respectively. In this study, we demonstrated that the PP obtained by combination ROC had a higher diagnostic efficacy than any single risk factor. The combination of coagulation indexes, globulins, tumor markers and bone ALP may greatly improve the diagnostic efficiency of BM due to GC.

**CONCLUSION**

Overall, coagulation markers (PT, aPTT and FDP), CEA and globulin are independent risk factors for BM due to GC. Patients with these risk factors should be screened for BM early, which could lead to significantly decreased mortality in patients with GC and BM.

**ARTICLE HIGHLIGHTS**

***Research background***

Bones are one of the most common targets for cancer metastasis. However, bone metastasis (BM) is often underdiagnosed because sensitive diagnostic imaging methods are recommended only after the onset of clinical symptoms. Patients with gastric cancer (GC), especially in advanced stages, are often in a hypercoagulable state.

***Research motivation***

The purpose of this study was to explore the predictive value of blood indicators on the risk of BM due to GC and to improve the diagnostic efficacy of BM due to GC by screening effective risk factors.

***Research objectives***

The purpose of this study was to explore whether coagulation indicators can be used as independent risk factors for predicting BM due to GC, thus promoting the early diagnosis and treatment of BM.

***Research methods***

We conducted a retrospective study and enrolled 454 patients in this study. Receiver operating characteristic (ROC) curves were used to assess diagnostic performance. Univariate and multivariate logistic regression analyses were used to evaluate the relationship between biomarkers and BM.

***Research results***

ROC curve analysis indicated that coagulation markers have similar or better diagnostic efficacy than traditional GC markers. Based on multivariate logistic regression analysis, prothrombin time, activated partial thromboplastin time and fibrin degradation products were independently associated with BM due to GC. Moreover, age, carcinoembryonic antigen, erythrocyte level and globulin were found to be risk factors of BM. Combining these indicators could improve the effectiveness of diagnosing BM.

***Research conclusions***

Coagulation markers (prothrombin time, activated partial thromboplastin time and fibrin degradation products), carcinoembryonic antigen and globulin were independent risk factors for BM due to GC. Patients with these risk factors should be screened early to detect BM due to GC and prevent bone-related events.

***Research perspectives***

Future research will explore the relationship and molecular mechanism between coagulation and tumor metastasis and explore new targets to block the process of tumor metastasis.

**REFERENCES**

1 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

2 **Mikami J**, Kimura Y, Makari Y, Fujita J, Kishimoto T, Sawada G, Nakahira S, Nakata K, Tsujie M, Ohzato H. Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis. *World J Surg Oncol* 2017; **15**: 8 [PMID: 28061855 DOI: 10.1186/s12957-016-1091-2]

3 **Imura Y**, Tateiwa D, Sugimoto N, Inoue A, Wakamatsu T, Outani H, Tanaka T, Tamiya H, Yagi T, Naka N, Okawa S, Tabuchi T, Takenaka S. Prognostic factors and skeletal-related events in patients with bone metastasis from gastric cancer. *Mol Clin Oncol* 2020; **13**: 31 [PMID: 32765878 DOI: 10.3892/mco.2020.2101]

4 **Turkoz FP**, Solak M, Kilickap S, Ulas A, Esbah O, Oksuzoglu B, Yalcin S. Bone metastasis from gastric cancer: the incidence, clinicopathological features, and influence on survival. *J Gastric Cancer* 2014; **14**: 164-172 [PMID: 25328761 DOI: 10.5230/jgc.2014.14.3.164]

5 **Qiu MZ**, Shi SM, Chen ZH, Yu HE, Sheng H, Jin Y, Wang DS, Wang FH, Li YH, Xie D, Zhou ZW, Yang DJ, Xu RH. Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER-based study. *Cancer Med* 2018; **7**: 3662-3672 [PMID: 29984918 DOI: 10.1002/cam4.1661]

6 **Lim SM**, Kim YN, Park KH, Kang B, Chon HJ, Kim C, Kim JH, Rha SY. Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. *BMC Cancer* 2016; **16**: 385 [PMID: 27377907 DOI: 10.1186/s12885-016-2415-x]

7 **Wu C**, Lin X, Li Z, Chen Z, Xie W, Zhang X, Wang X. A Diagnostic Nomogram Based on (18)F-FDG PET/CT for Bone Metastasis of Gastric Cancer. *Front Cell Dev Biol* 2021; **9**: 783466 [PMID: 34970546 DOI: 10.3389/fcell.2021.783466]

8 **Li Y**, Xu C, Yu Q. Risk factor analysis of bone metastasis in patients with non-small cell lung cancer. *Am J Transl Res* 2022; **14**: 6696-6702 [PMID: 36247263]

9 **Yin JJ**, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. *Cell Res* 2005; **15**: 57-62 [PMID: 15686629 DOI: 10.1038/sj.cr.7290266]

10 **Xiaobin C**, Zhaojun X, Tao L, Tianzeng D, Xuemei H, Fan Z, Chunyin H, Jianqiang H, Chen L. Analysis of Related Risk Factors and Prognostic Factors of Gastric Cancer with Bone Metastasis: A SEER-Based Study. *J Immunol Res* 2022; **2022**: 3251051 [PMID: 35211630 DOI: 10.1155/2022/3251051]

11 **Nakanishi H**, Araki N, Kuratsu S, Narahara H, Ishikawa O, Yoshikawa H. Skeletal metastasis in patients with gastric cancer. *Clin Orthop Relat Res* 2004: 208-212 [PMID: 15232450 DOI: 10.1097/01.blo.0000129159.65684.b3]

12 **Choi CW**, Lee DS, Chung JK, Lee MC, Kim NK, Choi KW, Koh CS. Evaluation of bone metastases by Tc-99m MDP imaging in patients with stomach cancer. *Clin Nucl Med* 1995; **20**: 310-314 [PMID: 7788986 DOI: 10.1097/00003072-199504000-00005]

13 **Wen L**, Li YZ, Zhang J, Zhou C, Yang HN, Chen XZ, Xu LW, Kong SN, Wang XW, Zhang HM. Clinical analysis of bone metastasis of gastric cancer: incidence, clinicopathological features and survival. *Future Oncol* 2019; **15**: 2241-2249 [PMID: 31215231 DOI: 10.2217/fon-2019-0039]

14 **Wang K**, Jiang X, Ren Y, Ma Z, Cheng X, Li F, Xiao J, Yu Z, Jiao Z. The significance of preoperative serum carcinoembryonic antigen levels in the prediction of lymph node metastasis and prognosis in locally advanced gastric cancer: a retrospective analysis. *BMC Gastroenterol* 2020; **20**: 100 [PMID: 32276616 DOI: 10.1186/s12876-020-01255-6]

15 **Ikeda Y**, Mori M, Adachi Y, Matsushima T, Sugimachi K, Saku M. Carcinoembryonic antigen (CEA) in stage IV gastric cancer as a risk factor for liver metastasis: a univariate and multivariate analysis. *J Surg Oncol* 1993; **53**: 235-238 [PMID: 8341054 DOI: 10.1002/jso.2930530409]

16 **Jin W**, Zhu M, Zheng Y, Wu Y, Ding X, Wu H, Ye J, Wu Y, Zhu Z, Song X. Perineural invasion, lactate dehydrogenase, globulin, and serum sodium predicting occult metastasis in oral cancer. *Oral Dis* 2022; **28**: 132-141 [PMID: 33289935 DOI: 10.1111/odi.13750]

17 **Chen J**, Zhou Y, Xu Y, Zhu HY, Shi YQ. Low pretreatment serum globulin may predict favorable prognosis for gastric cancer patients. *Tumour Biol* 2016; **37**: 3905-3911 [PMID: 26476541 DOI: 10.1007/s13277-015-3778-3]

18 **Falanga A**, Schieppati F, Russo D. Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer. *Semin Thromb Hemost* 2015; **41**: 756-764 [PMID: 26408922 DOI: 10.1055/s-0035-1564040]

19 **Yao Y**, Zhou Y, Yang Z, Shen H. [Risk Factors of Non-small Cell Lung Cancer with Bone Metastasis after Therapy]. *Zhongguo Fei Ai Za Zhi* 2018; **21**: 476-480 [PMID: 29945707 DOI: 10.3779/j.issn.1009-3419.2018.06.09]

20 **Gale AJ**, Gordon SG. Update on tumor cell procoagulant factors. *Acta Haematol* 2001; **106**: 25-32 [PMID: 11549774 DOI: 10.1159/000046586]

21 **Gil-Bernabé AM**, Lucotti S, Muschel RJ. Coagulation and metastasis: what does the experimental literature tell us? *Br J Haematol* 2013; **162**: 433-441 [PMID: 23691951 DOI: 10.1111/bjh.12381]

22 **Palumbo JS**, Degen JL. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. *Thromb Res* 2007; **120 Suppl 2**: S22-S28 [PMID: 18023710 DOI: 10.1016/S0049-3848(07)70127-5]

23 **Park JM**, Song KY, O JH, Kim WC, Choi MG, Park CH. Bone recurrence after curative resection of gastric cancer. *Gastric Cancer* 2013; **16**: 362-369 [PMID: 22961057 DOI: 10.1007/s10120-012-0193-y]

24 **Anderson JA**, Weitz JI. Hypercoagulable states. *Crit Care Clin* 2011; **27**: 933-952, vii [PMID: 22082521 DOI: 10.1016/j.ccc.2011.09.007]

25 **Jiang HG**, Li J, Shi SB, Chen P, Ge LP, Jiang Q, Tang XP. Value of fibrinogen and D-dimer in predicting recurrence and metastasis after radical surgery for non-small cell lung cancer. *Med Oncol* 2014; **31**: 22 [PMID: 24861920 DOI: 10.1007/s12032-014-0022-8]

26 **Tankó LB**, Karsdal MA, Christiansen C, Leeming DJ. Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers? *Cancer Metastasis Rev* 2006; **25**: 659-668 [PMID: 17160557 DOI: 10.1007/s10555-006-9024-0]

**Footnotes**

**Institutional review board statement:** This study was approved by the Ethics Committee of First Affiliated Hospital of Xi’an Jiaotong University (Approval No. 2015-046).

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

**Conflict-of-interest statement:** The authors declare that no competing interests exist.

**Data sharing statement:** Dataset available from the corresponding author at <zhangxinzh@stu.xjtu.edu.cn>.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** February 6, 2023

**First decision:** March 15, 2023

**Article in press:** May 6, 2023

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Seretis C, Greece; Tanabe S, Japan **S-Editor:** Yan JP **L-Editor:** A **P-Editor:** Zhang XD

**Figure Legends**

****

**Figure 1 Receiver operating characteristic analysis for the prediction of bone metastasis.** A-H: Area under the receiver operating characteristic (ROC) curve analysis indicated the diagnostic power of carcinoembryonic antigen (CEA) (A), age (B), erythrocyte level (C), globulin (D), prothrombin time (PT) (E), activated partial thromboplastin time (APTT) (F), fibrin degradation product (FDP) (G) and prediction probability (H) for bone metastasis. Prediction probability was obtained by binary logistic regression of CEA, age, erythrocyte level, globulin, PT, APTT and FDP. The area under the ROC curve of the prediction probability was 0.879 with a 95% confidence interval of 0.841-0.917. ROC: Receiver operating characteristic; FDP: Fibrin degradation product; PT: Prothrombin time; APTT: Activated partial thromboplastin time; CEA: Carcinoembryonic antigen.

**Table 1 Demographic and baseline characteristics of patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Overall, *n* = 454** | **No bone metastasis, *n* = 263** | **Bone metastasis, *n* = 191** | ***P* value** |
| Male sex | 335 (73.8) | 196 (74.5) | 139 (72.8) | 0.676 |
| Age, yr | 59 (50-67) | 61 (51-67) | 57 (49-66) | 0.046 |
| CEA, ng/mL | 3.53 (1.73-14.65) | 2.43 (1.35-4.89) | 5.29 (2.90-38.31) | < 0.001 |
| CA19-9, U/mL | 12.25 (6.30-46.88) | 9.89 (4.92-20.20) | 22.62 (9.73-113.35) | < 0.001 |
| CA72-4, U/mL | 3.39 (1.60-12.00) | 2.58 (1.57-6.78) | 7.09 (1.96-21.68) | < 0.001 |
| Erythrocyte, × 1012/L | 4.14 (3.65-4.57) | 4.27 (3.78-4.68) | 4.00 (3.50-4.39) | < 0.001 |
| Hemoglobin, g/L | 124 (106-139) | 127 (109-143) | 119 (103-133) | < 0.001 |
| Leukocyte, × 109/L | 5.69 (4.51-7.12) | 5.51 (4.43-6.76) | 6.20 (4.69-7.86) | 0.002 |
| Neutrophil, × 109/L | 3.54 (2.64-4.88) | 3.23 (2.51-4.33) | 4.04 (2.83-5.97) | < 0.001 |
| Lymphocyte, × 109/L | 1.37 (1.08-1.81) | 1.48 (1.12-1.95) | 1.30 (1.02-1.63) | 0.001 |
| Platelet, × 109/L | 196 (150-253) | 204 (160-260) | 180 (140-235) | 0.001 |
| Monocyte, × 109/L | 0.41 (0.30-0.54) | 0.42 (0.31-0.54) | 0.40 (0.30-0.55) | 0.713 |
| Glucose, mmol/L | 4.54 (4.17-5.07) | 4.40 (4.04-4.83) | 4.84 (4.39-5.55) | < 0.001 |
| [Albumin](file:///C%3A/Users/Administrator/AppData/Local/youdao/dict/Application/8.5.1.0/resultui/html/index.html#/javascript:;), g/L | 38.11 ± 4.96 | 37.80 ± 4.71 | 38.55 ± 5.26 | 0.113 |
| [Globulin](file:///C%3A/Users/Administrator/AppData/Local/youdao/dict/Application/8.5.1.0/resultui/html/index.html#/javascript:;), g/L | 26.4 (23.7-29.8) | 25.5 (22.8-28.2) | 28.8 (25.1-31.6) | < 0.001 |
| PT, s | 13.1 (12.5-13.8) | 12.8 (12.3-13.4) | 13.5 (13.0-14.4) | < 0.001 |
| PTR | 1.05 (0.99-1.10) | 1.03 (0.98-1.08) | 1.06 (1.01-1.12) | < 0.001 |
| INR | 1.05 (0.99-1.10) | 1.03 (0.98-1.08) | 1.07 (1.01-1.13) | < 0.001 |
| aPTT, s | 35.0 (31.5-38.1) | 33.5 (30.8-36.8) | 36.3 (33.7-39.1) | < 0.001 |
| TT, s | 16.3 (15.6-16.9) | 16.4 (15.7-17.0) | 16.0 (15.3-16.8) | < 0.001 |
| FIB, g/L | 3.32 (2.76-4.16) | 3.21 (2.62-3.82) | 3.63 (2.93-4.59) | < 0.001 |
| D-dimer, mg/L | 0.9 (0.3-2.5) | 0.5 (0.1-1.1) | 2.0 (0.8-6.6) | < 0.001 |
| FDP, mg/L | 1.9 (0.9-4.9) | 1.2 (0.7-2.5) | 4.5 (1.7-16.2) | < 0.001 |

Data are shown as number of cases and percentage or median and interquartile range. aPTT: Activated partial prothrombin time; CA19-9: Carbohydrate antigen 19-9; CA72-4: Carbohydrate antigen 72-4; CEA: Carcinoembryonic antigen; FDP: Fibrin degradation products; FIB: Fibrinogen; INR: International normalized ratio; PT: Prothrombin time; PTR: Prothrombin ratio; TT: Thrombin time.

**Table 2 Area under the receiver operating characteristic curves and cutoff values of diagnostic indicators at the maximum Youden index for bone metastasis**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | **AUC** | **95%CI** | **Cutoff** | **Sen** | **Spe** | **Youden index** | **PPV** | **NPV** | ***P* value** |
| Age | 0.558 | 0.501-0.616 | 59.5 | 0.546 | 0.583 | 0.129 | 0.433 | 0.546 | 0.046 |
| CEA | 0.694 | 0.639-0.748 | 3.97 | 0.649 | 0.711 | 0.36 | 0.665 | 0.711 | < 0.001 |
| CA19-9 | 0.673 | 0.617-0.729 | 12.81 | 0.655 | 0.649 | 0.304 | 0.614 | 0.649 | < 0.001 |
| CA72-4 | 0.624 | 0.560-0.688 | 6.71 | 0.518 | 0.747 | 0.265 | 0.603 | 0.747 | < 0.001 |
| Erythrocyte | 0.623 | 0.571-0.675 | 4.43 | 0.423 | 0.797 | 0.220 | 0.498 | 0.423 | < 0.001 |
| Hemoglobin | 0.599 | 0.547-0.651 | 133.50 | 0.427 | 0.759 | 0.186 | 0.488 | 0.427 | < 0.001 |
| Leukocyte | 0.587 | 0.532-0.641 | 6.28  | 0.492 | 0.685 | 0.177 | 0.529 | 0.685 | 0.002 |
| Neutrophil | 0.63 | 0.576-0.683 | 4.23 | 0.484 | 0.749 | 0.233 | 0.581 | 0.749 | < 0.001 |
| Lymphocyte | 0.591 | 0.539-0.644 | 1.43  | 0.552 | 0.642 | 0.194 | 0.508 | 0.552 | 0.001 |
| Platelet | 0.591 | 0.538-0.645 | 167.50 | 0.731 | 0.449 | 0.180 | 0.545 | 0.731 | 0.001 |
| Glucose | 0.664 | 0.613-0.716 | 4.82 | 0.524 | 0.748 | 0.272 | 0.595 | 0.748 | < 0.001 |
| [Globulin](file:///C%3A/Users/Administrator/AppData/Local/youdao/dict/Application/8.5.1.0/resultui/html/index.html#/javascript:;) | 0.675 | 0.624-0.726 | 28.75 | 0.500 | 0.814 | 0.314 | 0.655 | 0.814 | < 0.001 |
| PT | 0.738 | 0.692-0.784 | 13.25 | 0.651 | 0.709 | 0.360 | 0.618 | 0.709 | < 0.001 |
| PTR | 0.622 | 0.570-0.675 | 1.09 | 0.407 | 0.785 | 0.193 | 0.579 | 0.785 | < 0.001 |
| INR | 0.627 | 0.574-0.680 | 1.10 | 0.376 | 0.819 | 0.195 | 0.602 | 0.819 | < 0.001 |
| aPTT | 0.678 | 0.629-0.727 | 35.15 | 0.640 | 0.640 | 0.280 | 0.563 | 0.640 | < 0.001 |
| TT | 0.598 | 0.545-0.652 | 15.95 | 0.697 | 0.487 | 0.184 | 0.538 | 0.816 | < 0.001 |
| FIB | 0.616 | 0.562-0.669 | 4.06 | 0.423 | 0.820 | 0.243 | 0.630 | 0.820 | < 0.001 |
| D-dimer | 0.756 | 0.710-0.801 | 1.03 | 0.690 | 0.728 | 0.418 | 0.645 | 0.728 | < 0.001 |
| FDP | 0.768 | 0.722-0.814 | 2.75 | 0.668 | 0.801 | 0.469 | 0.706 | 0.801 | < 0.001 |
| PP | 0.879 | 0.841-0.917 | 0.364 | 0.831 | 0.806 | 0.637 | 0.745 | 0.806 | < 0.001 |

aPTT: Activated partial prothrombin time; AUC: Area under receiver operating characteristic curve; CA19-9: Carbohydrate antigen 19-9; CA72-4: Carbohydrate antigen 72-4; CEA: Carcinoembryonic antigen; CI: Confidence interval; FDP: Fibrin degradation products; FIB: Fibrinogen; INR: International normalized ratio; NPV: Negative predictive value; PP: Prediction probability; PPV: Positive predictive value; PT: Prothrombin time; PTR: Prothrombin ratio; Sen: Sensitivity; Spe: Specificity; TT: Thrombin time.

**Table 3 Univariate and multivariate binary logistic regression analyses of variables for bone metastasis**

|  |  |  |
| --- | --- | --- |
|  | **Univariate analysis** | **Multivariate analysis** |
| **Parameter** | **Odds ratio** | **95%CI** | ***P* value** | **Odds ratio** | **95%CI** | ***P* value** |
| Age | 0.594 | 0.398-0.887 | 0.011 | 0.392 | 0.203-0.756 | 0.005 |
| CEA | 4.559 | 2.931-7.090 | < 0.001 | 2.847 | 1.496-5.418 | 0.001 |
| CA19-9 | 3.511 | 2.271-5.429 | < 0.001 |  |  | 0.352 |
| CA72-4 | 3.176 | 1.995-5.056 | < 0.001 |  |  | 0.086 |
| Erythrocyte | 0.348 | 0.226-0.536 | < 0.001 | 0.482 | 0.240-0.966 | 0.040 |
| Hemoglobin | 0.425 | 0.281-0.645 | < 0.001 |  |  | 0.852 |
| Leukocyte | 2.102 | 1.426-3.099 | < 0.001 |  |  | 0.693 |
| Neutrophil | 2.798 | 1.872-4.183 | < 0.001 |  |  | 0.601 |
| Lymphocyte | 0.453 | 0.308-0.667 | < 0.001 |  |  | 0.575 |
| Platelet | 0.452 | 0.304-0.672 | < 0.001 |  |  | 0.066 |
| Glucose | 3.273 | 2.191-4.890 | < 0.001 |  |  | 0.087 |
| [Globulin](file:///C%3A/Users/Administrator/AppData/Local/youdao/dict/Application/8.5.1.0/resultui/html/index.html#/javascript:;) | 4.367 | 2.861-6.667 | < 0.001 | 4.253 | 2.114-8.558 | < 0.001 |
| PT | 4.536 | 3.038-6.774 | < 0.001 | 3.16 | 1.612-6.194 | 0.001 |
| PTR | 2.517 | 1.663-3.808 | < 0.001 |  |  | 0.145 |
| INR | 2.727 | 1.771-4.199 | < 0.001 |  |  | 0.072 |
| aPTT | 3.161 | 2.140-4.669 | < 0.001 | 2.234 | 1.157-4.313 | 0.017 |
| TT | 0.535 | 0.344-0.833 | 0.006 |  |  | 0.842 |
| FIB | 3.342 | 2.179-5.125 | < 0.001 |  |  | 0.193 |
| D-dimer | 5.952 | 3.939-8.993 | < 0.001 |  |  | 0.956 |
| FDP | 8.103 | 5.271-12.457 | < 0.001 | 3.17 | 1.637-6.139 | 0.001 |

The reference of parameters was set to be less than their cutoff values. aPTT: Activated partial prothrombin time; CA19-9: Carbohydrate antigen 19-9; CA72-4: Carbohydrate antigen 72-4; CEA: Carcinoembryonic antigen; CI: Confidence interval; FDP: Fibrin degradation products; FIB: Fibrinogen; INR: International normalized ratio; PT: Prothrombin time; PTR: Prothrombin ratio; TT: Thrombin time.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**